Senolytics shown to extend mouse healthspan (2015)
James Kirkland's team at Mayo Clinic reported in Aging Cell that a combination of dasatinib and quercetin selectively killed senescent cells in old mice, improving cardiovascular function and physical performance. The paper triggered a wave of geroscience startups and human pilot studies.
Two biotechs, Unity Biotechnology and Cleara Biotech, formed within two years. The first human pilot launched in 2018 in patients with idiopathic pulmonary fibrosis.
Senolytics remain in human trials a decade later, with mixed results. No senolytic has won FDA approval for an aging indication.
Same arc as the TTP finding: clean mouse data, fast pharma interest, slow translation. Reads as the most direct template for what comes next.
